Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2015013861
pages 315-327

Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology

Rimas J. Orentas
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
Crystal L. Mackall
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

ABSTRACT

After decades of basic research, immune-based therapeutics for the treatment of cancer are showing evidence of efficacy in clinical trials; several immunotherapeutics already incorporated into standard treatment regimens. Intensive research is underway to improve the efficacy of immunotherapeutics and to expand the application of immunotherapy to a wider array of cancers. The therapeutic options that comprise immunotherapy for cancer are vast and span monoclonal antibodies, tumor vaccines, adoptive cellular therapies, as well as therapies aimed at reversing immunosuppression and enhancing immune reactivity globally and/or locally within the tumor microenvironment. In pediatric cancer, monoclonal antibodies have demonstrated efficacy in hematologic malignancies, and neuroblastoma and bispecific antibodies that activate resident T cells, as well as adoptive cell therapy, have shown recent exciting results for the treatment of acute lymphoblastic leukemia in childhood. This review discusses the basic principles of tumor immunology driving clinical development of new immunotherapies, describes immunotherapeutics with demonstrated efficacy and several currently in clinical trials, and highlight agents that seem to be most promising for the treatment of pediatric cancer.


Articles with similar content:

Adoptive Immunotherapy of Cancer Using Chimeric Antigen Receptor−Engineered T Cells
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
John Maher, Daniela Achkova
Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
Elizabeth R. Lawlor, Poul H. Sorensen
Structure and Biological Activity of Botulinum Neurotoxins and Application to Cancer Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 3-4
Ester Fernandez-Salas, Kei Roger Aoki
Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Robert L. Sutherland, Andrew Stone, Elizabeth A . Musgrove
Druggable Targets in Pancreatic Adenocarcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Cristina Napoli, Stefania Nobili, Ida Landini, Gabriele Perrone, Enrico Mini, Renato Tassi